Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 311

1.

Bio-soliton model that predicts non-thermal electromagnetic frequency bands, that either stabilize or destabilize living cells.

Geesink JH, Meijer DKF.

Electromagn Biol Med. 2017;36(4):357-378. doi: 10.1080/15368378.2017.1389752.

PMID:
29164985
2.

On a generalized Levinthal's paradox: The role of long- and short range interactions in complex bio-molecular reactions, including protein and DNA folding.

Melkikh AV, Meijer DKF.

Prog Biophys Mol Biol. 2018 Jan;132:57-79. doi: 10.1016/j.pbiomolbio.2017.09.018. Epub 2017 Sep 23. Review.

PMID:
28951190
3.

Inhibition of renal rho kinase attenuates ischemia/reperfusion-induced injury.

Prakash J, de Borst MH, Lacombe M, Opdam F, Klok PA, van Goor H, Meijer DK, Moolenaar F, Poelstra K, Kok RJ.

J Am Soc Nephrol. 2008 Nov;19(11):2086-97. doi: 10.1681/ASN.2007070794. Epub 2008 Jul 23.

4.

Liver slices as a model to study fibrogenesis and test the effects of anti-fibrotic drugs on fibrogenic cells in human liver.

van de Bovenkamp M, Groothuis GM, Meijer DK, Olinga P.

Toxicol In Vitro. 2008 Apr;22(3):771-8. doi: 10.1016/j.tiv.2007.11.019. Epub 2007 Dec 8.

PMID:
18207697
5.

Cell-specific delivery of a transforming growth factor-beta type I receptor kinase inhibitor to proximal tubular cells for the treatment of renal fibrosis.

Prakash J, de Borst MH, van Loenen-Weemaes AM, Lacombe M, Opdam F, van Goor H, Meijer DK, Moolenaar F, Poelstra K, Kok RJ.

Pharm Res. 2008 Oct;25(10):2427-39. doi: 10.1007/s11095-007-9515-x. Epub 2008 Jan 9.

PMID:
18183478
6.

Targeting of stabilized plasmid lipid particles to hepatocytes in vivo by means of coupled lactoferrin.

Weeke-Klimp AH, Bartsch M, Morselt HW, Van Veen-Hof I, Meijer DK, Scherphof GL, Kamps JA.

J Drug Target. 2007 Nov;15(9):585-94.

PMID:
17968712
7.

A phase I/IIa study with succinylated human serum albumin (Suc-HSA), a candidate HIV-1 fusion inhibitor.

Vermeulen JN, Meijer DK, Over J, Lange J, Proost JH, Bakker HI, Beljaars L, Wit FW, Prins JM.

Antivir Ther. 2007;12(2):273-8.

PMID:
17503670
8.

A novel lipid-based drug carrier targeted to the non-parenchymal cells, including hepatic stellate cells, in the fibrotic livers of bile duct ligated rats.

Adrian JE, Kamps JA, Scherphof GL, Meijer DK, van Loenen-Weemaes AM, Reker-Smit C, Terpstra P, Poelstra K.

Biochim Biophys Acta. 2007 Jun;1768(6):1430-9. Epub 2007 Apr 6.

9.

Local inhibition of liver fibrosis by specific delivery of a platelet-derived growth factor kinase inhibitor to hepatic stellate cells.

Gonzalo T, Beljaars L, van de Bovenkamp M, Temming K, van Loenen AM, Reker-Smit C, Meijer DK, Lacombe M, Opdam F, Kéri G, Orfi L, Poelstra K, Kok RJ.

J Pharmacol Exp Ther. 2007 Jun;321(3):856-65. Epub 2007 Mar 16.

PMID:
17369283
10.

Delivery of viral vectors to hepatic stellate cells in fibrotic livers using HVJ envelopes fused with targeted liposomes.

Adrian JE, Kamps JA, Poelstra K, Scherphof GL, Meijer DK, Kaneda Y.

J Drug Target. 2007 Jan;15(1):75-82.

PMID:
17365276
11.

Effects of a new bioactive lipid-based drug carrier on cultured hepatic stellate cells and liver fibrosis in bile duct-ligated rats.

Adrian JE, Poelstra K, Scherphof GL, Meijer DK, van Loenen-Weemaes AM, Reker-Smit C, Morselt HW, Zwiers P, Kamps JA.

J Pharmacol Exp Ther. 2007 May;321(2):536-43. Epub 2007 Feb 21.

PMID:
17314198
12.

Liver fibrosis in vitro: cell culture models and precision-cut liver slices.

Van de Bovenkamp M, Groothuis GM, Meijer DK, Olinga P.

Toxicol In Vitro. 2007 Jun;21(4):545-57. Epub 2007 Jan 3. Review.

PMID:
17289342
13.

Precision-cut fibrotic rat liver slices as a new model to test the effects of anti-fibrotic drugs in vitro.

van de Bovenkamp M, Groothuis GM, Meijer DK, Olinga P.

J Hepatol. 2006 Nov;45(5):696-703. Epub 2006 May 26.

PMID:
16828918
14.

Human liver slices as an in vitro model to study toxicity-induced hepatic stellate cell activation in a multicellular milieu.

van de Bovenkamp M, Groothuis GMM, Meijer DKF, Slooff MJH, Olinga P.

Chem Biol Interact. 2006 Jul 25;162(1):62-69. doi: 10.1016/j.cbi.2006.05.006. Epub 2006 May 17.

PMID:
16815347
15.

Intracellular delivery of the p38 mitogen-activated protein kinase inhibitor SB202190 [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole] in renal tubular cells: a novel strategy to treat renal fibrosis.

Prakash J, Sandovici M, Saluja V, Lacombe M, Schaapveld RQ, de Borst MH, van Goor H, Henning RH, Proost JH, Moolenaar F, Këri G, Meijer DK, Poelstra K, Kok RJ.

J Pharmacol Exp Ther. 2006 Oct;319(1):8-19. Epub 2006 Jun 28.

PMID:
16807361
16.

Selective targeting of pentoxifylline to hepatic stellate cells using a novel platinum-based linker technology.

Gonzalo T, Talman EG, van de Ven A, Temming K, Greupink R, Beljaars L, Reker-Smit C, Meijer DK, Molema G, Poelstra K, Kok RJ.

J Control Release. 2006 Mar 10;111(1-2):193-203. Epub 2006 Feb 7.

PMID:
16466667
17.

Gliotoxin non-selectively induces apoptosis in fibrotic and normal livers.

Hagens WI, Olinga P, Meijer DK, Groothuis GM, Beljaars L, Poelstra K.

Liver Int. 2006 Mar;26(2):232-9.

PMID:
16448462
18.

The antiproliferative drug doxorubicin inhibits liver fibrosis in bile duct-ligated rats and can be selectively delivered to hepatic stellate cells in vivo.

Greupink R, Bakker HI, Bouma W, Reker-Smit C, Meijer DK, Beljaars L, Poelstra K.

J Pharmacol Exp Ther. 2006 May;317(2):514-21. Epub 2006 Jan 26.

PMID:
16439617
19.

Interaction of targeted liposomes with primary cultured hepatic stellate cells: Involvement of multiple receptor systems.

Adrian JE, Poelstra K, Scherphof GL, Molema G, Meijer DK, Reker-Smit C, Morselt HW, Kamps JA.

J Hepatol. 2006 Mar;44(3):560-7. Epub 2005 Oct 19.

PMID:
16368158
20.

On the role and fate of LPS-dephosphorylating activity in the rat liver.

Tuin A, Huizinga-Van der Vlag A, van Loenen-Weemaes AM, Meijer DK, Poelstra K.

Am J Physiol Gastrointest Liver Physiol. 2006 Feb;290(2):G377-85. Epub 2005 Oct 13.

21.

Prediction of the pharmacokinetics of succinylated human serum albumin in man from in vivo disposition data in animals and in vitro liver slice incubations.

Proost JH, Beljaars L, Olinga P, Swart PJ, Kuipers ME, Reker-Smit C, Groothuis GM, Meijer DK.

Eur J Pharm Sci. 2006 Feb;27(2-3):123-32. Epub 2005 Oct 10.

PMID:
16219448
22.

Cell-specific targeting of lipid-based carriers for ODN and DNA.

Bartsch M, Weeke-Klimp AH, Meijer DK, Scherphof GL, Kamps JA.

J Liposome Res. 2005;15(1-2):59-92. Review.

PMID:
16194928
23.

Bioanalysis and pharmacokinetics of the p38 MAPkinase inhibitor SB202190 in rats.

Prakash J, Saluja V, Visser J, Moolenaar F, Meijer DK, Poelstra K, Kok RJ.

J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Nov 5;826(1-2):220-5. Epub 2005 Sep 23.

PMID:
16183336
24.

EUFEPS conference on drug transporters at Copenhagen: integrative approaches in ADME research.

Meijer DK, Lennernäs H.

Eur J Pharm Sci. 2005 Sep;26(1):130-43. No abstract available.

PMID:
16161216
25.

Studies on the targeted delivery of the antifibrogenic compound mycophenolic acid to the hepatic stellate cell.

Greupink R, Bakker HI, Reker-Smit C, van Loenen-Weemaes AM, Kok RJ, Meijer DK, Beljaars L, Poelstra K.

J Hepatol. 2005 Nov;43(5):884-92. Epub 2005 Jun 4.

PMID:
16083988
26.

Characterization of rat small intestinal and colon precision-cut slices as an in vitro system for drug metabolism and induction studies.

van de Kerkhof EG, de Graaf IA, de Jager MH, Meijer DK, Groothuis GM.

Drug Metab Dispos. 2005 Nov;33(11):1613-20. Epub 2005 Jul 28.

PMID:
16051733
27.

EUFEPS report. Contribution of academic research to discovery and development of medicines: current status and future opportunities.

Couvreur P, Barguer D, Crommelin DJ, Duchêne D, Engels JW, Kerr DJ, Krogsgaard-Larsen P, Meijer DK, Paoletti R, Wagner E; EUFEPS.

Eur J Pharm Sci. 2005 Feb;24(2-3):245-52. No abstract available.

PMID:
15776539
28.

Renal targeting of captopril using subcutaneous administration of captopril-lysozyme conjugate.

Prakash J, Kok RJ, van Loenen-Weemaes A, Haas M, Proost JH, Meijer DK, Moolenaar F.

J Control Release. 2005 Jan 3;101(1-3):350-1. No abstract available.

PMID:
15765569
29.

Precision-cut liver slices as a new model to study toxicity-induced hepatic stellate cell activation in a physiologic milieu.

van de Bovenkamp M, Groothuis GM, Draaisma AL, Merema MT, Bezuijen JI, van Gils MJ, Meijer DK, Friedman SL, Olinga P.

Toxicol Sci. 2005 May;85(1):632-8. Epub 2005 Feb 23.

PMID:
15728706
30.

Antiviral activity of human lactoferrin: inhibition of alphavirus interaction with heparan sulfate.

Waarts BL, Aneke OJ, Smit JM, Kimata K, Bittman R, Meijer DK, Wilschut J.

Virology. 2005 Mar 15;333(2):284-92.

31.

Renal-selective delivery and angiotensin-converting enzyme inhibition by subcutaneously administered captopril-lysozyme.

Prakash J, van Loenen-Weemaes AM, Haas M, Proost JH, Meijer DK, Moolenaar F, Poelstra K, Kok RJ.

Drug Metab Dispos. 2005 May;33(5):683-8. Epub 2005 Jan 26.

PMID:
15673598
32.

Stabilized lipid coated lipoplexes for the delivery of antisense oligonucleotides to liver endothelial cells in vitro and in vivo.

Bartsch M, Weeke-Klimp AH, Hoenselaar EP, Stuart MC, Meijer DK, Scherphof GL, Kamps JA.

J Drug Target. 2004;12(9-10):613-21.

PMID:
15621687
33.

Optimized targeting of polyethylene glycol-stabilized anti-intercellular adhesion molecule 1 oligonucleotide/lipid particles to liver sinusoidal endothelial cells.

Bartsch M, Weeke-Klimp AH, Morselt HW, Kimpfler A, Asgeirsdóttir SA, Schubert R, Meijer DK, Scherphof GL, Kamps JA.

Mol Pharmacol. 2005 Mar;67(3):883-90. Epub 2004 Dec 14.

PMID:
15598973
34.

A new technique for preparing precision-cut slices from small intestine and colon for drug biotransformation studies.

de Kanter R, Tuin A, van de Kerkhof E, Martignoni M, Draaisma AL, de Jager MH, de Graaf IA, Meijer DK, Groothuis GM.

J Pharmacol Toxicol Methods. 2005 Jan-Feb;51(1):65-72.

PMID:
15596116
35.

Pharmacokinetic and biodistribution profile of recombinant human interleukin-10 following intravenous administration in rats with extensive liver fibrosis.

Rachmawati H, Beljaars L, Reker-Smit C, Van Loenen-Weemaes AM, Hagens WI, Meijer DK, Poelstra K.

Pharm Res. 2004 Nov;21(11):2072-8.

PMID:
15587930
36.

Inhibition of cytomegalovirus infection by lactoferrin in vitro and in vivo.

Beljaars L, van der Strate BW, Bakker HI, Reker-Smit C, van Loenen-Weemaes AM, Wiegmans FC, Harmsen MC, Molema G, Meijer DK.

Antiviral Res. 2004 Sep;63(3):197-208.

PMID:
15451188
37.

RGD-modified anti-CD3 antibodies redirect cytolytic capacity of cytotoxic T lymphocytes toward alphavbeta3-expressing endothelial cells.

Schraa AJ, Kok RJ, Botter SM, Withoff S, Meijer DK, de Leij LF, Molema G.

Int J Cancer. 2004 Nov 1;112(2):279-85.

38.

Protection against an Escherichia coli-induced sepsis by alkaline phosphatase in mice.

Verweij WR, Bentala H, Huizinga-van der Vlag A, Miek van Loenen-Weemaes A, Kooi K, Meijer DK, Poelstra K.

Shock. 2004 Aug;22(2):174-9.

PMID:
15257092
39.

LPS-induced downregulation of MRP2 and BSEP in human liver is due to a posttranscriptional process.

Elferink MG, Olinga P, Draaisma AL, Merema MT, Faber KN, Slooff MJ, Meijer DK, Groothuis GM.

Am J Physiol Gastrointest Liver Physiol. 2004 Nov;287(5):G1008-16. Epub 2004 Jun 17.

40.

Prediction of whole-body metabolic clearance of drugs through the combined use of slices from rat liver, lung, kidney, small intestine and colon.

De Kanter R, Monshouwer M, Draaisma AL, De Jager MH, de Graaf IA, Proost JH, Meijer DK, Groothuis GM.

Xenobiotica. 2004 Mar;34(3):229-41.

PMID:
15204696
41.

A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo.

Ogawara K, Rots MG, Kok RJ, Moorlag HE, Van Loenen AM, Meijer DK, Haisma HJ, Molema G.

Hum Gene Ther. 2004 May;15(5):433-43.

PMID:
15144574
42.

Dissemination of rat cytomegalovirus through infected granulocytes and monocytes in vitro and in vivo.

van der Strate BW, Hillebrands JL, Lycklama à Nijeholt SS, Beljaars L, Bruggeman CA, Van Luyn MJ, Rozing J, The TH, Meijer DK, Molema G, Harmsen MC.

J Virol. 2003 Oct;77(20):11274-8.

43.

The preferential homing of a platelet derived growth factor receptor-recognizing macromolecule to fibroblast-like cells in fibrotic tissue.

Beljaars L, Weert B, Geerts A, Meijer DK, Poelstra K.

Biochem Pharmacol. 2003 Oct 1;66(7):1307-17.

PMID:
14505810
44.

The pharmacokinetic and biological activity profile of dexamethasone targeted to sinusoidal endothelial and Kupffer cells.

Melgert BN, Weert B, Schellekens H, Meijer DK, Poelstra K.

J Drug Target. 2003 Jan;11(1):1-10.

PMID:
12852435
45.

Drug uptake systems in liver and kidney.

van Montfoort JE, Hagenbuch B, Groothuis GM, Koepsell H, Meier PJ, Meijer DK.

Curr Drug Metab. 2003 Jun;4(3):185-211. Review.

PMID:
12769665
46.

Specific drug delivery to the kidney.

Haas M, Moolenaar F, Meijer DK, de Zeeuw D.

Cardiovasc Drugs Ther. 2002 Dec;16(6):489-96. Review.

PMID:
12766381
47.

Delivery of pharmacologically active dexamethasone into activated endothelial cells by dexamethasone-anti-E-selectin immunoconjugate.

Asgeirsdóttir SA, Kok RJ, Everts M, Meijer DK, Molema G.

Biochem Pharmacol. 2003 May 15;65(10):1729-39.

PMID:
12754109
48.

Synergy of bovine lactoferrin with the anti-cytomegalovirus drug cidofovir in vitro.

van der Strate BW, De Boer FM, Bakker HI, Meijer DK, Molema G, Harmsen MC.

Antiviral Res. 2003 Apr;58(2):159-65.

PMID:
12742576
49.

Effects of anti-proteinuric therapy with angiotensin-converting-enzyme inhibition on renal protein catabolism in the adriamycin-induced nephrotic rat.

Haas M, de Boer E, de Jong PE, Moolenaar F, Meijer DK, de Zeeuw D.

Clin Sci (Lond). 2003 Jul;105(1):51-7.

PMID:
12636872
50.

Renal targeting of captopril selectively enhances the intrarenal over the systemic effects of ACE inhibition in rats.

Haverdings RG, Haas M, Navis GJ, van Loenen-Weemaes AM, Meijer DK, de Zeeuw D, Moolenaar F.

Br J Pharmacol. 2003 Feb;138(4):531. No abstract available.

Supplemental Content

Loading ...
Support Center